Clinical trial · Observational
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study
NCT01232881CI-TRIAL-00004741terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): funding terminated
Summary
Brief summary (as posted)
This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Serum Sample | Procedure | — | UNRESOLVED |
| Tumor Sample | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Tumor and Serum Collection
- description
- Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block. Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
- interventionNames
- Procedure: Tumor Sample
- Procedure: Serum Sample
Primary outcomes (1)
- measure
- To correlate tumor gene expression (genomic profile) with response to lonafarnib in patients with advanced breast cancer
- timeFrame
- 24 months
Secondary outcomes (4)
- measure
- To correlate serum and tumor proteomic profiles with response to lonafarnib
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. * Age \> 18 years. * Planned treatment with lonafarnib for metastatic breast cancer. * Must consent to have a biopsy performed to obtain fresh tissue or be able to identify a formalin fixed paraffin embedded (FFPE) tissue block in which tumor samples can be obtained to complete the testing for this study. Exclusion Criteria: * Planned treatment with any other treatment regimen
References
Publications (0)
Data not yet available
No reference posted for this study.